ID   BPL1_HUMAN              Reviewed;         726 AA.
AC   P50747; B2RAH1; D3DSG6; Q99451;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=Biotin--protein ligase;
DE            EC=6.3.4.-;
DE   AltName: Full=Biotin apo-protein ligase;
DE   Includes:
DE     RecName: Full=Biotin--[methylmalonyl-CoA-carboxytransferase] ligase;
DE              EC=6.3.4.9;
DE   Includes:
DE     RecName: Full=Biotin--[propionyl-CoA-carboxylase [ATP-hydrolyzing]] ligase;
DE              EC=6.3.4.10;
DE     AltName: Full=Holocarboxylase synthetase;
DE              Short=HCS;
DE   Includes:
DE     RecName: Full=Biotin--[methylcrotonoyl-CoA-carboxylase] ligase;
DE              EC=6.3.4.11;
DE   Includes:
DE     RecName: Full=Biotin--[acetyl-CoA-carboxylase] ligase;
DE              EC=6.3.4.15;
GN   Name=HLCS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT HLCS DEFICIENCY PRO-237.
RC   TISSUE=Liver;
RX   PubMed=7842009; DOI=10.1038/ng1094-122;
RA   Suzuki Y., Aoki Y., Ishida Y., Chiba Y., Iwamatsu A., Kishino T.,
RA   Niikawa N., Matsubara Y., Narisawa K.;
RT   "Isolation and characterization of mutations in the human
RT   holocarboxylase synthetase cDNA.";
RL   Nat. Genet. 8:122-128(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=9037601; DOI=10.1101/gr.7.1.47;
RA   Ohira M., Seki N., Nagase T., Suzuki E., Nomura N., Ohara O.,
RA   Hattori M., Sakaki Y., Eki T., Murakami Y., Saito T., Ichikawa H.,
RA   Ohki M.;
RT   "Gene identification in 1.6-Mb region of the Down syndrome region on
RT   chromosome 21.";
RL   Genome Res. 7:47-58(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Shibuya K., Kudoh J., Minoshima S., Kawasaki K., Nakatoh E.,
RA   Shintani A., Asakawa S., Shimizu N.;
RT   "Genomic sequencing of 1.2-Mb region on human chromosome 21q22.2.";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS HLCS DEFICIENCY ASP-42;
RP   PRO-237; GLU-333; SER-360; CYS-456; SER-470; TRP-508; GLY-547;
RP   MET-550; SER-581; THR-610 DEL AND TYR-634, AND CHARACTERIZATION OF
RP   VARIANTS HLCS DEFICIENCY ASP-42; SER-360; CYS-456; SER-470; GLY-547
RP   AND TYR-634.
RX   PubMed=11735028; DOI=10.1007/s004390100603;
RA   Yang X., Aoki Y., Li X., Sakamoto O., Hiratsuka M., Kure S.,
RA   Taheri S., Christensen E., Inui K., Kubota M., Ohira M., Ohki M.,
RA   Kudoh J., Kawasaki K., Shibuya K., Shintani A., Asakawa S.,
RA   Minoshima S., Shimizu N., Narisawa K., Matsubara Y., Suzuki Y.;
RT   "Structure of human holocarboxylase synthetase gene and mutation
RT   spectrum of holocarboxylase synthetase deficiency.";
RL   Hum. Genet. 109:526-534(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thalamus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-92.
RC   TISSUE=Brain;
RX   PubMed=9503011; DOI=10.1006/geno.1997.5146;
RA   Dahmane N., Ait-Ghezala G., Gosset P., Chamoun Z.,
RA   Dufresne-Zacharia M.-C., Lopes C., Rabatel N., Gassanova-Maugenre S.,
RA   Chettouh Z., Abramowski V., Fayet E., Yaspo M.-L., Korn B.,
RA   Blouin J.-L., Lehrach H., Poustka A., Antonarakis S.E., Sinet P.-M.,
RA   Creau N., Delabar J.-M.;
RT   "Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21
RT   involved in Down syndrome.";
RL   Genomics 48:12-23(1998).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   VARIANT HLCS DEFICIENCY PRO-237.
RX   PubMed=8541348; DOI=10.1016/0925-4439(95)00082-8;
RA   Aoki Y., Suzuki Y., Sakamoto O., Li X., Takahashi K., Ohtake A.,
RA   Sakuta R., Ohura T., Miyabayashi S., Narisawa K.;
RT   "Molecular analysis of holocarboxylase synthetase deficiency: a
RT   missense mutation and a single base deletion are predominant in
RT   Japanese patients.";
RL   Biochim. Biophys. Acta 1272:168-174(1995).
RN   [15]
RP   VARIANTS HLCS DEFICIENCY ARG-216; ASP-363; TRP-508; GLU-518; MET-550
RP   AND ASN-571.
RX   PubMed=8817339; DOI=10.1093/hmg/5.7.1011;
RA   Dupuis L., Leon-Del-Rio A., Leclerc D., Campeau E., Sweetman L.,
RA   Saudubray J.-M., Herman G., Gibson K.M., Gravel R.A.;
RT   "Clustering of mutations in the biotin-binding region of
RT   holocarboxylase synthetase in biotin-responsive multiple carboxylase
RT   deficiency.";
RL   Hum. Mol. Genet. 5:1011-1016(1996).
RN   [16]
RP   VARIANTS HLCS DEFICIENCY PRO-237 AND MET-550.
RX   PubMed=9396568; DOI=10.1203/00006450-199712000-00021;
RA   Aoki Y., Suzuki Y., Li X., Sakamoto O., Chikaoka H., Takita S.,
RA   Narisawa K.;
RT   "Characterization of mutant holocarboxylase synthetase (HCS): a Km for
RT   biotin was not elevated in a patient with HCS deficiency.";
RL   Pediatr. Res. 42:849-854(1997).
RN   [17]
RP   VARIANTS HLCS DEFICIENCY GLU-333; ILE-462; ASN-571; SER-581 AND
RP   THR-610 DEL.
RX   PubMed=10190325; DOI=10.1007/s004390050927;
RA   Aoki Y., Li X., Sakamoto O., Hiratsuka M., Akaishi H., Xu L.,
RA   Briones P., Suormala T., Baumgartner E.R., Suzuki Y., Narisawa K.;
RT   "Identification and characterization of mutations in patients with
RT   holocarboxylase synthetase deficiency.";
RL   Hum. Genet. 104:143-148(1999).
RN   [18]
RP   BIOPHYSICOCHEMICAL PROPERTIES, VARIANTS HLCS DEFICIENCY PRO-183;
RP   ARG-216; PRO-237; GLU-333; ASP-363; SER-581 AND THR-610 DEL, AND
RP   CHARACTERIZATION OF VARIANTS HLCS DEFICIENCY PRO-183; ARG-216;
RP   PRO-237; GLU-333; ASP-363; SER-581 AND THR-610 DEL.
RX   PubMed=10590022; DOI=10.1203/00006450-199912000-00006;
RA   Sakamoto O., Suzuki Y., Li X., Aoki Y., Hiratsuka M., Suormala T.,
RA   Baumgartner E.R., Gibson K.M., Narisawa K.;
RT   "Relationship between kinetic properties of mutant enzyme and
RT   biochemical and clinical responsiveness to biotin in holocarboxylase
RT   synthetase deficiency.";
RL   Pediatr. Res. 46:671-676(1999).
RN   [19]
RP   VARIANTS HLCS DEFICIENCY ARG-216; LYS-511; SER-581 AND ARG-582.
RX   PubMed=12124727; DOI=10.1002/ajmg.10532;
RA   Morrone A., Malvagia S., Donati M.A., Funghini S., Ciani F., Pela I.,
RA   Boneh A., Peters H., Pasquini E., Zammarchi E.;
RT   "Clinical findings and biochemical and molecular analysis of four
RT   patients with holocarboxylase synthetase deficiency.";
RL   Am. J. Med. Genet. 111:10-18(2002).
RN   [20]
RP   VARIANTS HLCS DEFICIENCY TRP-508; MET-550 AND ASN-634.
RX   PubMed=12633764; DOI=10.1016/S0009-9120(02)00432-0;
RA   Tang N.L.S., Hui J., Yong C.K.K., Wong L.T.K., Applegarth D.A.,
RA   Vallance H.D., Law L.K., Fung S.L.M., Mak T.W.L., Sung Y.M.,
RA   Cheung K.L., Fok T.F.;
RT   "A genomic approach to mutation analysis of holocarboxylase synthetase
RT   gene in three Chinese patients with late-onset holocarboxylase
RT   synthetase deficiency.";
RL   Clin. Biochem. 36:145-149(2003).
RN   [21]
RP   VARIANTS HLCS DEFICIENCY TYR-615 AND GLY-715.
RX   PubMed=16134170; DOI=10.1002/humu.20204;
RA   Suzuki Y., Yang X., Aoki Y., Kure S., Matsubara Y.;
RT   "Mutations in the holocarboxylase synthetase gene HLCS.";
RL   Hum. Mutat. 26:285-290(2005).
RN   [22]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-42.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [23]
RP   CHARACTERIZATION OF VARIANT HLCS DEFICIENCY ARG-216.
RX   PubMed=18429047; DOI=10.1002/humu.20766;
RA   Bailey L.M., Ivanov R.A., Jitrapakdee S., Wilson C.J., Wallace J.C.,
RA   Polyak S.W.;
RT   "Reduced half-life of holocarboxylase synthetase from patients with
RT   severe multiple carboxylase deficiency.";
RL   Hum. Mutat. 29:E47-E57(2008).
RN   [24]
RP   VARIANTS HLCS DEFICIENCY ARG-505 AND TRP-508.
RX   PubMed=20095979; DOI=10.1111/j.1399-0004.2009.01357.x;
RA   Tammachote R., Janklat S., Tongkobpetch S., Suphapeetiporn K.,
RA   Shotelersuk V.;
RT   "Holocarboxylase synthetase deficiency: novel clinical and molecular
RT   findings.";
RL   Clin. Genet. 78:88-93(2010).
RN   [25]
RP   VARIANT HLCS DEFICIENCY TRP-241.
RX   PubMed=25690727; DOI=10.1007/8904_2014_367;
RA   De Castro M., Zand D.J., Lichter-Konecki U., Kirmse B.;
RT   "Severe neonatal holocarboxylase synthetase deficiency in west african
RT   siblings.";
RL   JIMD Rep. 20:1-4(2015).
CC   -!- FUNCTION: Post-translational modification of specific protein by
CC       attachment of biotin. Acts on various carboxylases such as acetyl-
CC       CoA-carboxylase, pyruvate carboxylase, propionyl CoA carboxylase,
CC       and 3-methylcrotonyl CoA carboxylase.
CC   -!- CATALYTIC ACTIVITY: ATP + biotin + apo-[methylmalonyl-CoA:pyruvate
CC       carboxytransferase] = AMP + diphosphate + [methylmalonyl-
CC       CoA:pyruvate carboxytransferase].
CC   -!- CATALYTIC ACTIVITY: ATP + biotin + apo-[propionyl-CoA:carbon-
CC       dioxide ligase (ADP-forming)] = AMP + diphosphate + [propionyl-
CC       CoA:carbon-dioxide ligase (ADP-forming)].
CC   -!- CATALYTIC ACTIVITY: ATP + biotin + apo-[3-methylcrotonoyl-
CC       CoA:carbon-dioxide ligase (ADP-forming)] = AMP + diphosphate + [3-
CC       methylcrotonoyl-CoA:carbon-dioxide ligase (ADP-forming)].
CC   -!- CATALYTIC ACTIVITY: ATP + biotin + apo-[acetyl-CoA:carbon-dioxide
CC       ligase (ADP-forming)] = AMP + diphosphate + [acetyl-CoA:carbon-
CC       dioxide ligase (ADP-forming)].
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=224 nM for biotin {ECO:0000269|PubMed:10590022};
CC         Vmax=143.9 pmol/min/mg enzyme {ECO:0000269|PubMed:10590022};
CC   -!- SUBUNIT: Monomer.
CC   -!- INTERACTION:
CC       O00763:ACACB; NbExp=4; IntAct=EBI-3915568, EBI-2211739;
CC       Q9NUX5:POT1; NbExp=2; IntAct=EBI-3915568, EBI-752420;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Mitochondrion.
CC   -!- TISSUE SPECIFICITY: Mostly expressed in muscle, placenta, in
CC       lesser extent in the brain, kidney, pancreas, liver and lung.
CC   -!- DISEASE: Holocarboxylase synthetase deficiency (HLCS deficiency)
CC       [MIM:253270]: A neonatal form of multiple carboxylase deficiency,
CC       an autosomal recessive disorder of biotin metabolism,
CC       characterized by ketoacidosis, hyperammonemia, excretion of
CC       abnormal organic acid metabolites, and dermatitis. In
CC       holocarboxylase synthetase deficiency, clinical and biochemical
CC       symptoms improve dramatically with administration of biotin.
CC       {ECO:0000269|PubMed:10190325, ECO:0000269|PubMed:10590022,
CC       ECO:0000269|PubMed:11735028, ECO:0000269|PubMed:12124727,
CC       ECO:0000269|PubMed:12633764, ECO:0000269|PubMed:16134170,
CC       ECO:0000269|PubMed:20095979, ECO:0000269|PubMed:25690727,
CC       ECO:0000269|PubMed:7842009, ECO:0000269|PubMed:8541348,
CC       ECO:0000269|PubMed:8817339, ECO:0000269|PubMed:9396568}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the biotin--protein ligase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AK307940; Type=Frameshift; Positions=169; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D23672; BAA04902.1; -; mRNA.
DR   EMBL; D87328; BAA13332.1; -; mRNA.
DR   EMBL; AP000697; BAA89434.1; -; Genomic_DNA.
DR   EMBL; AP000703; BAA89434.1; JOINED; Genomic_DNA.
DR   EMBL; AP000701; BAA89434.1; JOINED; Genomic_DNA.
DR   EMBL; AP000698; BAA89434.1; JOINED; Genomic_DNA.
DR   EMBL; AB063285; BAB68550.1; -; Genomic_DNA.
DR   EMBL; AK307940; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK314189; BAG36868.1; -; mRNA.
DR   EMBL; AP001726; BAA95510.1; -; Genomic_DNA.
DR   EMBL; AP001727; BAA95511.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09731.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09732.1; -; Genomic_DNA.
DR   EMBL; BC060787; AAH60787.1; -; mRNA.
DR   EMBL; AJ001864; CAA05056.1; -; mRNA.
DR   CCDS; CCDS13647.1; -.
DR   PIR; S50833; S50833.
DR   RefSeq; NP_000402.3; NM_000411.6.
DR   RefSeq; NP_001229713.1; NM_001242784.1.
DR   RefSeq; NP_001229714.1; NM_001242785.1.
DR   RefSeq; XP_005261012.1; XM_005260955.3.
DR   RefSeq; XP_005261013.1; XM_005260956.3.
DR   RefSeq; XP_006724057.1; XM_006723994.2.
DR   RefSeq; XP_006724058.1; XM_006723995.1.
DR   RefSeq; XP_011527840.1; XM_011529538.1.
DR   RefSeq; XP_011527841.1; XM_011529539.2.
DR   RefSeq; XP_011527843.1; XM_011529541.2.
DR   RefSeq; XP_016883819.1; XM_017028330.1.
DR   UniGene; Hs.371350; -.
DR   UniGene; Hs.732538; -.
DR   ProteinModelPortal; P50747; -.
DR   SMR; P50747; -.
DR   BioGrid; 109386; 9.
DR   IntAct; P50747; 6.
DR   MINT; MINT-3018588; -.
DR   STRING; 9606.ENSP00000338387; -.
DR   BindingDB; P50747; -.
DR   ChEMBL; CHEMBL2062354; -.
DR   DrugBank; DB00121; Biotin.
DR   iPTMnet; P50747; -.
DR   PhosphoSitePlus; P50747; -.
DR   BioMuta; HLCS; -.
DR   DMDM; 1705499; -.
DR   EPD; P50747; -.
DR   MaxQB; P50747; -.
DR   PaxDb; P50747; -.
DR   PeptideAtlas; P50747; -.
DR   PRIDE; P50747; -.
DR   Ensembl; ENST00000336648; ENSP00000338387; ENSG00000159267.
DR   Ensembl; ENST00000399120; ENSP00000382071; ENSG00000159267.
DR   Ensembl; ENST00000612277; ENSP00000479939; ENSG00000159267.
DR   GeneID; 3141; -.
DR   KEGG; hsa:3141; -.
DR   UCSC; uc002yvs.4; human.
DR   CTD; 3141; -.
DR   DisGeNET; 3141; -.
DR   GeneCards; HLCS; -.
DR   HGNC; HGNC:4976; HLCS.
DR   HPA; HPA017379; -.
DR   MalaCards; HLCS; -.
DR   MIM; 253270; phenotype.
DR   MIM; 609018; gene.
DR   neXtProt; NX_P50747; -.
DR   OpenTargets; ENSG00000159267; -.
DR   Orphanet; 79242; Holocarboxylase synthetase deficiency.
DR   PharmGKB; PA29310; -.
DR   eggNOG; KOG1536; Eukaryota.
DR   eggNOG; COG0340; LUCA.
DR   GeneTree; ENSGT00390000002960; -.
DR   HOGENOM; HOG000095254; -.
DR   HOVERGEN; HBG004872; -.
DR   InParanoid; P50747; -.
DR   KO; K01942; -.
DR   OMA; RDPLMQW; -.
DR   OrthoDB; EOG091G0G5R; -.
DR   PhylomeDB; P50747; -.
DR   TreeFam; TF105860; -.
DR   Reactome; R-HSA-196780; Biotin transport and metabolism.
DR   ChiTaRS; HLCS; human.
DR   GenomeRNAi; 3141; -.
DR   PRO; PR:P50747; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000159267; -.
DR   CleanEx; HS_HLCS; -.
DR   ExpressionAtlas; P50747; baseline and differential.
DR   Genevisible; P50747; HS.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005652; C:nuclear lamina; IDA:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0009374; F:biotin binding; IDA:UniProtKB.
DR   GO; GO:0004077; F:biotin-[acetyl-CoA-carboxylase] ligase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004078; F:biotin-[methylcrotonoyl-CoA-carboxylase] ligase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004079; F:biotin-[methylmalonyl-CoA-carboxytransferase] ligase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004080; F:biotin-[propionyl-CoA-carboxylase (ATP-hydrolyzing)] ligase activity; IDA:UniProtKB.
DR   GO; GO:0018271; F:biotin-protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0006768; P:biotin metabolic process; TAS:Reactome.
DR   GO; GO:0008283; P:cell proliferation; IMP:UniProtKB.
DR   GO; GO:0071110; P:histone biotinylation; IDA:UniProtKB.
DR   GO; GO:0016570; P:histone modification; IDA:UniProtKB.
DR   GO; GO:0009305; P:protein biotinylation; IDA:UniProtKB.
DR   GO; GO:0070781; P:response to biotin; IDA:UniProtKB.
DR   InterPro; IPR019197; Biotin-prot_ligase_N.
DR   InterPro; IPR004408; Biotin_CoA_COase_ligase.
DR   InterPro; IPR003142; BPL_C.
DR   InterPro; IPR004143; BPL_LPL_catalytic.
DR   PANTHER; PTHR12835:SF10; PTHR12835:SF10; 1.
DR   Pfam; PF02237; BPL_C; 1.
DR   Pfam; PF03099; BPL_LplA_LipB; 1.
DR   Pfam; PF09825; BPL_N; 1.
DR   TIGRFAMs; TIGR00121; birA_ligase; 1.
DR   PROSITE; PS51733; BPL_LPL_CATALYTIC; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Cytoplasm; Disease mutation; Ligase;
KW   Mitochondrion; Multifunctional enzyme; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    726       Biotin--protein ligase.
FT                                /FTId=PRO_0000064979.
FT   DOMAIN      463    652       BPL/LPL catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01067}.
FT   MOD_RES     147    147       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     299    299       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      42     42       E -> D (in HLCS deficiency and a breast
FT                                cancer sample; somatic mutation;
FT                                conserves enzymatic wild-type activity;
FT                                unknown pathological significance;
FT                                dbSNP:rs61732504).
FT                                {ECO:0000269|PubMed:11735028,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035800.
FT   VARIANT     183    183       R -> P (in HLCS deficiency; has normal or
FT                                low KM values for biotin (non-KM
FT                                mutant)). {ECO:0000269|PubMed:10590022}.
FT                                /FTId=VAR_046507.
FT   VARIANT     216    216       L -> R (in HLCS deficiency; has normal or
FT                                low KM values for biotin (non-KM mutant);
FT                                growth of patients' fibroblasts is
FT                                compromised compared with normal
FT                                fibroblasts; patients cells are not
FT                                sensitive to biotin-depletion from the
FT                                media; growth rates cannot be restored by
FT                                re-administration of biotin; enzyme
FT                                activity is severely compromised and
FT                                cannot be increased by additional biotin;
FT                                turn-over rate for the mutant protein is
FT                                double that of wild-type enzyme;
FT                                dbSNP:rs28934602).
FT                                {ECO:0000269|PubMed:10590022,
FT                                ECO:0000269|PubMed:12124727,
FT                                ECO:0000269|PubMed:18429047,
FT                                ECO:0000269|PubMed:8817339}.
FT                                /FTId=VAR_021218.
FT   VARIANT     237    237       L -> P (in HLCS deficiency; has normal or
FT                                low KM values for biotin (non-KM mutant);
FT                                dbSNP:rs119103227).
FT                                {ECO:0000269|PubMed:10590022,
FT                                ECO:0000269|PubMed:11735028,
FT                                ECO:0000269|PubMed:7842009,
FT                                ECO:0000269|PubMed:8541348,
FT                                ECO:0000269|PubMed:9396568}.
FT                                /FTId=VAR_005084.
FT   VARIANT     241    241       G -> W (in HLCS deficiency).
FT                                {ECO:0000269|PubMed:25690727}.
FT                                /FTId=VAR_073074.
FT   VARIANT     333    333       V -> E (in HLCS deficiency; <10%
FT                                activity; has normal or low KM values for
FT                                biotin (non-KM mutant)).
FT                                {ECO:0000269|PubMed:10190325,
FT                                ECO:0000269|PubMed:10590022,
FT                                ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_009196.
FT   VARIANT     360    360       R -> S (in HLCS deficiency; 22% activity;
FT                                shows elevated KM values for biotin (KM
FT                                mutant) compared with that of the wild-
FT                                type form).
FT                                {ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_046508.
FT   VARIANT     363    363       V -> D (in HLCS deficiency; has normal or
FT                                low KM values for biotin (non-KM mutant);
FT                                dbSNP:rs769499327).
FT                                {ECO:0000269|PubMed:10590022,
FT                                ECO:0000269|PubMed:8817339}.
FT                                /FTId=VAR_046509.
FT   VARIANT     456    456       Y -> C (in HLCS deficiency; 0.2%
FT                                activity; dbSNP:rs781603756).
FT                                {ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_046510.
FT   VARIANT     462    462       T -> I (in HLCS deficiency; <10%
FT                                activity). {ECO:0000269|PubMed:10190325}.
FT                                /FTId=VAR_009197.
FT   VARIANT     470    470       L -> S (in HLCS deficiency; 4.3%
FT                                activity). {ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_046511.
FT   VARIANT     505    505       G -> R (in HLCS deficiency).
FT                                {ECO:0000269|PubMed:20095979}.
FT                                /FTId=VAR_073075.
FT   VARIANT     508    508       R -> W (in HLCS deficiency;
FT                                dbSNP:rs119103229).
FT                                {ECO:0000269|PubMed:11735028,
FT                                ECO:0000269|PubMed:12633764,
FT                                ECO:0000269|PubMed:20095979,
FT                                ECO:0000269|PubMed:8817339}.
FT                                /FTId=VAR_013009.
FT   VARIANT     511    511       N -> K (in HLCS deficiency).
FT                                {ECO:0000269|PubMed:12124727}.
FT                                /FTId=VAR_021219.
FT   VARIANT     518    518       G -> E (in HLCS deficiency).
FT                                {ECO:0000269|PubMed:8817339}.
FT                                /FTId=VAR_046512.
FT   VARIANT     547    547       V -> G (in HLCS deficiency; 3.4%
FT                                activity). {ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_046513.
FT   VARIANT     550    550       V -> M (in HLCS deficiency;
FT                                dbSNP:rs119103231).
FT                                {ECO:0000269|PubMed:11735028,
FT                                ECO:0000269|PubMed:12633764,
FT                                ECO:0000269|PubMed:8817339,
FT                                ECO:0000269|PubMed:9396568}.
FT                                /FTId=VAR_009198.
FT   VARIANT     571    571       D -> N (in HLCS deficiency; almost no
FT                                activity; dbSNP:rs119103228).
FT                                {ECO:0000269|PubMed:10190325,
FT                                ECO:0000269|PubMed:8817339}.
FT                                /FTId=VAR_009199.
FT   VARIANT     581    581       G -> S (in HLCS deficiency; <10%
FT                                activity; dbSNP:rs119103230).
FT                                {ECO:0000269|PubMed:10190325,
FT                                ECO:0000269|PubMed:10590022,
FT                                ECO:0000269|PubMed:11735028,
FT                                ECO:0000269|PubMed:12124727}.
FT                                /FTId=VAR_009200.
FT   VARIANT     582    582       G -> R (in HLCS deficiency;
FT                                dbSNP:rs376899782).
FT                                {ECO:0000269|PubMed:12124727}.
FT                                /FTId=VAR_021220.
FT   VARIANT     610    610       Missing (in HLCS deficiency; 14% of
FT                                activity; shows elevated KM values for
FT                                biotin (KM mutant) compared with that of
FT                                the wild-type form).
FT                                {ECO:0000269|PubMed:10190325,
FT                                ECO:0000269|PubMed:10590022,
FT                                ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_009201.
FT   VARIANT     615    615       D -> Y (in HLCS deficiency).
FT                                {ECO:0000269|PubMed:16134170}.
FT                                /FTId=VAR_046514.
FT   VARIANT     634    634       D -> N (in HLCS deficiency;
FT                                dbSNP:rs149399432).
FT                                {ECO:0000269|PubMed:12633764}.
FT                                /FTId=VAR_046515.
FT   VARIANT     634    634       D -> Y (in HLCS deficiency; 12%
FT                                activity). {ECO:0000269|PubMed:11735028}.
FT                                /FTId=VAR_046516.
FT   VARIANT     715    715       D -> G (in HLCS deficiency).
FT                                {ECO:0000269|PubMed:16134170}.
FT                                /FTId=VAR_046517.
FT   CONFLICT    209    209       P -> T (in Ref. 5; AK307940).
FT                                {ECO:0000305}.
FT   CONFLICT    463    463       K -> R (in Ref. 5; BAG36868).
FT                                {ECO:0000305}.
FT   CONFLICT    558    558       E -> K (in Ref. 2; BAA13332).
FT                                {ECO:0000305}.
SQ   SEQUENCE   726 AA;  80760 MW;  855B8E52106D675F CRC64;
     MEDRLHMDNG LVPQKIVSVH LQDSTLKEVK DQVSNKQAQI LEPKPEPSLE IKPEQDGMEH
     VGRDDPKALG EEPKQRRGSA SGSEPAGDSD RGGGPVEHYH LHLSSCHECL ELENSTIESV
     KFASAENIPD LPYDYSSSLE SVADETSPER EGRRVNLTGK APNILLYVGS DSQEALGRFH
     EVRSVLADCV DIDSYILYHL LEDSALRDPW TDNCLLLVIA TRESIPEDLY QKFMAYLSQG
     GKVLGLSSSF TFGGFQVTSK GALHKTVQNL VFSKADQSEV KLSVLSSGCR YQEGPVRLSP
     GRLQGHLENE DKDRMIVHVP FGTRGGEAVL CQVHLELPPS SNIVQTPEDF NLLKSSNFRR
     YEVLREILTT LGLSCDMKQV PALTPLYLLS AAEEIRDPLM QWLGKHVDSE GEIKSGQLSL
     RFVSSYVSEV EITPSCIPVV TNMEAFSSEH FNLEIYRQNL QTKQLGKVIL FAEVTPTTMR
     LLDGLMFQTP QEMGLIVIAA RQTEGKGRGG NVWLSPVGCA LSTLLISIPL RSQLGQRIPF
     VQHLMSVAVV EAVRSIPEYQ DINLRVKWPN DIYYSDLMKI GGVLVNSTLM GETFYILIGC
     GFNVTNSNPT ICINDLITEY NKQHKAELKP LRADYLIARV VTVLEKLIKE FQDKGPNSVL
     PLYYRYWVHS GQQVHLGSAE GPKVSIVGLD DSGFLQVHQE GGEVVTVHPD GNSFDMLRNL
     ILPKRR
//
